Indication
Synvisc-One is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information
Before trying Synvisc-One, tell your doctor if you have had an allergic reaction, such as swelling of the face, tongue or throat, respiratory difficulty, rash, itching or hives to SYNVISC or any hyaluronan-based products.

Please see additional Important Safety Information on page 10.
Please see Patient Information on page 11.
YOU DON’T HAVE TO SETTLE FOR YOUR OA KNEE PAIN

It’s time to explore different treatment options.

Talking to your doctor is the best way to start exploring your treatment options. And when you do, keep in mind:

**Osteoarthritis (OA) knee pain affects everyone differently**

An X-ray can show your grade or stage of osteoarthritis, but your level of pain isn’t necessarily connected to it. Your OA could be mild with a great deal of pain or severe with little pain. Your doctor is relying on you to give them a clear description of how your knee feels.¹

**OA is caused by more than just cartilage loss**

In knees with osteoarthritis, the cartilage protecting the ends of the bones gradually deteriorates, joint fluid loses its shock-absorbing qualities, and bones may begin to rub against each other—all of which may cause the OA knee pain you feel.²

**3 signs it might be time for a different treatment:**

1. Knee pain forces you to give things up
2. Knee pain keeps you from exercising
3. Current treatments are falling short

*Please see page 9 for additional information about the Synvisc-One clinical trials.
Please see additional Important Safety Information on page 10.
Please see Patient Information on page 11.
Synvisc-One® (hylan G-F 20) is a different way to treat OA knee pain

Synvisc-One lubricates and cushions your knee, and can provide **up to 6 months** of OA knee pain relief with just one injection.\(^a,b,*\)

**Available as 3 separate injections, SYNVISC® (hylan G-F 20) has a demonstrated safety profile and high level of patient satisfaction**

81% of patients rated SYNVISC as a “good” or “very good” therapy at 3 weeks after the first injection.\(^3,c,*\)

This is based on a large, observational study assessing its tolerability and short-term effectiveness. Adverse reactions were reported in 4.2% of patients.\(^3,c,*\)

When you’re ready to find a solution to your OA knee pain, ask your doctor if Synvisc-One is right for you.

**Important Safety Information (cont’d)**

Allergic reactions, some which can be potentially severe, have been reported during the use of Synvisc-One.

---

**TELL YOUR DOCTOR**

- How often the pain occurs
- How it affects your activities
- If your current treatment isn’t working
What is Synvisc-One?
Synvisc-One is a one-injection treatment that supplements the fluid in your knee to help lubricate and cushion the joint. It is one of the most prescribed viscosupplements and has been shown to improve OA knee pain for up to 6 months with just one injection.\textsuperscript{a,b,*}

What is Synvisc-One made from?
The injection contains a gel-like mixture made from a substance called hyaluronan (pronounced hy-al-u-ROE-nan) that comes from chicken combs.

Hyaluronan is a natural substance found in the body and is present in very high amounts in joints. The body’s own hyaluronan acts like a lubricant and a shock absorber in the joint and is needed for the joint to work properly.

When should I consider Synvisc-One?
Synvisc-One is for people with knee OA who have not received enough pain relief from diet, exercise, and over-the-counter pain medication. If you’ve tried these options and are still feeling OA knee pain, tell your doctor and ask if Synvisc-One could help.
What are the side effects?
The most common side effects are pain, swelling, heat, redness, and/or fluid build-up around the knee. In a medical study, fewer than 6% of patients experienced those side effects, which were generally mild and did not last long.\(^*\)

Is Synvisc-One safe?
In the pivotal clinical trial, Synvisc-One patients experienced a similar frequency of adverse reactions compared to patients who received the placebo. Fewer than 6% of Synvisc-One patients experienced side effects, which were generally mild and did not last long.\(^*\)

Important Safety Information (cont’d)
Should not be used in patients with an infected knee joint, skin disease or infection around the area where the injection will be given, and should be used with caution when there is swelling of the legs due to problems with venous stasis or lymphatic drainage.
How is Synvisc-One given?
Synvisc-One is a single-dose treatment that is injected directly into your knee.

What is the procedure like?
Each injection takes a few minutes and can be done in your doctor’s office.

Will the injection hurt?
Your doctor will likely apply a numbing agent before your Synvisc-One injection. You may feel some pressure, but it shouldn’t be painful.

Is it covered by insurance?
Synvisc-One is covered by Medicare and most insurance plans.

SEE FOR YOURSELF
Watch a video of a real patient’s injection at SynviscOne.com/video.
What happens after the injection?

You can resume normal day-to-day activities immediately after the injection, but you should avoid any strenuous activities for about 48 hours. Please consult your doctor regarding the appropriate time to resume such activities.

Important Safety Information (cont’d)

Synvisc-One is only for injection into the knee, performed by a doctor or other qualified health care professional. Synvisc-One has not been tested to show pain relief in joints other than the knee. Tell your doctor if you are allergic to products from birds – such as feathers, eggs or poultry – or if your leg is swollen or infected.

SYNVISC-ONE IS A LOCALIZED TREATMENT FOR YOUR CHRONIC OA KNEE PAIN

Systemic treatments such as acetaminophen and opioids may have adverse effects throughout the body that a localized treatment like Synvisc-One does not.4-6

Please be sure to consult with your doctor on any potential side effects for any treatment you consider.
KNOW WHAT TO EXPECT

What happens after a Synvisc-One® (hylan G-F 20) injection?

In the first 48 hours after your Synvisc-One injection:

• You should be able to resume your normal day-to-day activities
• You should avoid activities that put excessive strain on your knee, such as jogging, lifting, or prolonged standing
• If you have any mild pain or swelling at the injection site, place an ice pack on your knee as recommended by your doctor

Please consult with your doctor if you have any concerns and/or have additional side effects.

ASK YOUR DOCTOR ABOUT AN ALTERNATIVE SOLUTION

Synvisc-One is a product made from a natural substance that lubricates and cushions your knee joint.

*Please see page 9 for additional information about the Synvisc-One clinical trials.

Please see additional Important Safety Information on page 10.
Please see Patient Information on page 11.
In the months following an injection:

• Everyone responds differently, but in a medical study, many patients experienced OA knee pain relief starting one month after their injection.\(^7\, a,b,*\)

• Synvisc-One can provide up to 6 months of OA knee pain relief.\(^a,b,*\)

• Synvisc-One can be repeated safely. In a medical study involving 160 patients, 77 received a second injection of Synvisc-One.\(^a,b,*\)

• When your osteoarthritis knee pain returns, talk to your doctor to see if Synvisc-One is right for you

Important Safety Information (cont’d)

Synvisc-One has not been tested in children (≤21 years old), pregnant women or women who are nursing. You should tell your doctor if you think you are pregnant or if you are nursing a child.
The following reported adverse events (AEs) are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

N=253 (Synvisc-One + arthrocentesis=124, phosphate-buffered saline placebo + arthrocentesis=129), single 6-mL injection. Primary endpoint: Change from baseline over 26 weeks in the Western Ontario and McMaster Universities Osteoarthritis Index (pain) score using a 5-point Likert scale where 0=no pain and 4=extreme pain. Improvements from baseline were -0.84 with Synvisc-One and -0.69 with saline (P=0.047) (36% improvement from baseline for Synvisc-One vs 29% improvement with saline). The incidence of AEs was similar in the 2 groups (Synvisc-One, n=70, 56.9%; saline, n=79, 60.8%). There were no severe AEs in the Synvisc-One group. The most commonly reported AEs were arthralgia, arthritis, arthropathy, and gait disturbance.

Tolerability was assessed by the occurrence of AEs, both local and systemic, including their severity and relatedness to treatment, at visits 2, 3, and 4 (3 weeks after the first injection). Treatment-related AEs were reported in 4.2% of patients (2.4% of injections). Most AEs were mild (21.4%) to moderate (40.3%) and included joint effusion, joint swelling, arthralgia, joint warmth, and injection site erythema.


Study parameters for Synvisc-One® (hylan G-F 20) pivotal clinical trial

The following reported adverse events (AEs) are among those that may occur in association with intra-articular injections, including Synvisc-One: arthralgia, joint stiffness, joint effusion, joint swelling, joint warmth, injection site pain, arthritis, arthropathy, and gait disturbance.

N=253 (Synvisc-One + arthrocentesis=124, phosphate-buffered saline placebo + arthrocentesis=129), single 6-mL injection. Primary endpoint: Change from baseline over 26 weeks in the Western Ontario and McMaster Universities Osteoarthritis Index A (pain) score using a 5-point Likert scale where 0=no pain and 4=extreme pain. Improvements from baseline were -0.84 with Synvisc-One and -0.69 with saline (P=0.047) (36% improvement from baseline for Synvisc-One vs 29% improvement with saline). The incidence of AEs was similar in the 2 groups (Synvisc-One, n=70, 56.9%; saline, n=79, 60.8%). There were no severe AEs in the Synvisc-One group. The most commonly reported AEs were arthralgia, arthritis, arthropathy, injection site pain, and joint effusion.

Tolerability was assessed by the occurrence of AEs, both local and systemic, including their severity and relatedness to treatment, at visits 2, 3, and 4 (3 weeks after the first injection). Treatment-related AEs were reported in 4.2% of patients (2.4% of injections). Most AEs were mild (21.4%) to moderate (40.3%) and included joint effusion, joint swelling, arthralgia, joint warmth, and injection site erythema.
**Indication**

Synvisc-One® (hylan G-F 20) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

**Important Safety Information**

Before trying Synvisc-One, tell your doctor if you have had an allergic reaction, such as swelling of the face, tongue or throat, respiratory difficulty, rash, itching or hives to SYNVISC or any hyaluronan-based products. Allergic reactions, some which can be potentially severe, have been reported during the use of Synvisc-One. Should not be used in patients with an infected knee joint, skin disease or infection around the area where the injection will be given, and should be used with caution when there is swelling of the legs due to problems with venous stasis or lymphatic drainage.

Synvisc-One is only for injection into the knee, performed by a doctor or other qualified health care professional. Synvisc-One has not been tested to show pain relief in joints other than the knee. Tell your doctor if you are allergic to products from birds – such as feathers, eggs or poultry – or if your leg is swollen or infected.

Synvisc-One has not been tested in children (≤21 years old), pregnant women or women who are nursing. You should tell your doctor if you think you are pregnant or if you are nursing a child.

Talk to your doctor before resuming strenuous weight-bearing activities after treatment.

The side effects sometimes seen after Synvisc-One include (<2% each): pain, swelling, heat, redness, and/or fluid build-up in or around the knee. Tell your doctor if you experience any side effects after treatment with Synvisc-One.
Be sure to read the following important information carefully. This information does not take the place of your doctor’s advice. If you do not understand this information or want to know more, ask your doctor.

**Glossary of Terms**

**Hyaluronan (pronounced hy-al-u-ROE-nan):** is a natural substance that is present in very high amounts in joints. It acts like a lubricant and a shock absorber in the joint and is needed for the joint to work properly.

**Non-steroidal anti-inflammatory drugs:** also known as “NSAIDs”; medication used to treat pain or swelling. There are many examples of NSAIDs, including (but not limited to) aspirin and ibuprofen. Some of these are over-the-counter drugs, and some can only be obtained by prescription.

**Osteoarthritis (pronounced OS-te-o-arth-RI-tis):** (OA) is a type of arthritis that involves the wearing down of cartilage (the protective covering on the ends of your bones) and loss of cushioning fluid in the joint.

**Table of Contents**

- Glossary of Terms
- Table of Contents
- What is the Synvisc-One product?
- How is the Synvisc-One product used? (Indications)
- How is the Synvisc-One product given?
- Are there any reasons why I should not receive a Synvisc-One injection? (Contraindications)
- What should my doctor warn me about?
- What are the risks of getting a Synvisc-One injection?
- What are the benefits of getting a Synvisc-One injection?
- What do I need to do after I get a Synvisc-One injection?
- What other treatments are available for OA?
  - Non-drug treatments
  - Drug therapy
- When should you call your doctor? (Troubleshooting)
- What adverse events were observed in the clinical study?
- How do I get more information about the Synvisc-One product? (User Assistance)

**What is the Synvisc-One product?**

Synvisc-One is a gel-like mixture that comes in a syringe containing 6 mL (1 ½ teaspoon) and is injected into your knee. It is made up of hylan A fluid, hylan B gel, and salt water. Hylan A and hylan B are made from a substance called hyaluronan (pronounced hy-al-u-ROE-nan), also known as sodium hyaluronate that comes from chicken combs. Hyaluronan is a natural substance found in the body and is present in very high amounts in joints. The body’s own hyaluronan acts like a lubricant and a shock absorber in the joint and is needed for the joint to work properly.
How is the Synvisc-One product used? (Indications)
The FDA-approved indication for Synvisc-One is:
Synvisc-One is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

How is the Synvisc-One product given?
Your doctor will inject Synvisc-One into your knee.

Are there any reasons why I should not receive a Synvisc-One injection? (Contraindications)
Your doctor will determine if there is any reason why you are not an appropriate candidate for Synvisc-One. You should be aware that Synvisc-One:

• Should not be used in patients who have had any prior allergic reactions to SYNVISC, Synvisc-One or any hyaluronan-based products. Signs of an allergic reaction may include swelling of your face, tongue, or throat; difficulty breathing or swallowing; shortness of breath; wheezing; chest pain; a tightness in your throat; sleepiness; rash; itching; hives; flushing; and/or fever.
• Should not be used in patients with a knee joint infection, skin disease or infection around the area where the injection will be given.

What should my doctor warn me about?
The following are important treatment considerations for you to discuss with your doctor and understand in order to help avoid unsatisfactory results and complications:

• Synvisc-One is only for injection into the knee, performed by a doctor or other qualified health care professional. Synvisc-One has not been tested to show pain relief in joints other than the knee.
• Synvisc-One has not been tested to show better pain relief when combined with other injected medicines.
• Tell your doctor if you are allergic to products from birds such as feathers, eggs, and poultry.
• Tell your doctor if you have significant swelling or blood clots in the leg.
• SYNVISC should be used with caution when there is evidence of lymphatic or venous stasis in the leg to be injected.
• Synvisc-One has not been tested in pregnant women, or women who are nursing. You should tell your doctor if you think you are pregnant, or if you are nursing a child.
• Synvisc-One has not been tested in children (≤21 years of age).

What are the risks of getting a Synvisc-One injection?
The side effects (also called reactions) sometimes seen after any injection into the knee, including Synvisc-One, include: pain, swelling, heat, redness, and/or fluid build-up around the knee. These reactions are generally mild and do not last long. Reactions are generally treated by resting and applying ice to the injected knee. Sometimes it is necessary to give pain relievers by mouth such as acetaminophen or NSAIDs, or to give injections of steroids, or to remove fluid from the knee joint. Patients rarely
undergo arthroscopy (a surgical inspection of the knee joint) or other medical procedures related to these reactions.

Other side effects seen with SYNVISC® or Synvisc-One® are: rashes, hives, itching, muscle pain/cramps, flushing and/or swelling of your face, fast heart beat, nausea (or feeling sick to your stomach), dizziness, fever, chills, headache, difficulty breathing, swelling in your arms and/or legs, prickly feeling of your skin, and in rare cases a low number of platelets in the blood (platelets are a type of blood cell that are needed to help your blood clot when you are cut or injured). Allergic reactions, some which can be potentially severe, were observed during the use of Synvisc-One.

Rare cases of knee joint infection have been reported after SYNVISC injections. If any of the above side effects or symptoms appear after you are given Synvisc-One, or if you have any other problems, you should call your doctor.

**What are the benefits of getting a Synvisc-One injection?**

As shown in a medical study of 253 patients with osteoarthritis (OA) of the knee, where approximately half received either a single injection of Synvisc-One or an injection of the same volume of salt water (a “Saline Control” injection), the major benefits of Synvisc-One are pain relief and improvement in other symptoms related to OA of the knee.

**What do I need to do after I get a Synvisc-One injection?**

It is recommended you avoid strenuous activities (for example, high-impact sports such as tennis or jogging) or prolonged weight-bearing activities for approximately 48 hours following the injection. You should consult your doctor regarding the appropriate time to resume such activities.

**What other treatments are available for OA?**

If you have OA, there are other things you can do besides getting Synvisc-One. These include:

- **Non-drug treatments**
  - Avoiding activities that cause knee pain
  - Exercise or physical therapy
  - Weight loss
  - Removal of excess fluid from your knee

- **Drug therapy**
  - Pain relievers such as acetaminophen and narcotics
  - Drugs that reduce inflammation (signs of inflammation are swelling, pain or redness), such as aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs, for example ibuprofen and naproxen)
  - Steroids that are injected directly into your knee

**When should I call my doctor? (Troubleshooting)**

If any of the side effects or symptoms described above appear after you are given Synvisc-One, or if you have any other problems, you should call your doctor.
What did the clinical studies show?

A study was conducted in 6 countries outside the United States with 21 physicians. The patients in the study had mild to moderate knee OA, moderate to severe pain, and did not have sufficient relief of their pain and symptoms with medications taken by mouth.

A total of 253 patients in the study were assigned by chance to receive either a single injection of Synvisc-One (n=123 patients), or an injection of the same volume of salt water (a “Saline Control” injection) (n=130 patients). Neither the patients nor the doctors evaluating them knew which treatment they received. Any fluid that was present in the patient’s knee was removed before the injection. The patients were seen by their doctor at standard times over 6 months. Information was collected about how much pain they were experiencing doing various types of activities, how much they were limited in their daily activities by their OA, and on their overall condition. Their doctor also provided an overall rating of their OA.

The main measure of the study was how much pain the subjects had doing five common types of activities over the 6 months duration of the study. Daily activity limitations and overall evaluations were also compared between the group of patients receiving Synvisc-One injection and the group receiving salt water injection. The study showed that patients receiving Synvisc-One had significantly less pain over 6 months, and felt significantly better than the patients who received the salt water injections. The difference in pain score reduction from baseline to 6 months between the Synvisc-One and salt water control injection was 0.15 out of a 5 point scale for the measurement of OA pain in the knee.

What adverse events were observed in the clinical study?

The following are the most common adverse events that occurred during the clinical trial of Synvisc-One:

- Pain in the knee or at the injection site
- Stiffness, swelling or warmth in or around the knee
- Changes in the way that you walk (e.g., limping)

Severe adverse events were not observed in the Synvisc-One trial. Joint infections did not occur in the injected knee in the Synvisc-One clinical trial. The most commonly occurring adverse events outside of the injected knee were headache, back pain, sore throat and the flu. One patient had a single episode of feeling faint.

How do I get more information about the Synvisc-One product? (User Assistance)

If you have any questions or would like to find out more about Synvisc-One, you may call Sanofi at 1-888-3-SYNVISC (1-888-379-6847) or visit www.synvisc.com.

Manufactured by Genzyme Corporation, a Sanofi Company 1-888-3-SYNVISC
Indication
Synvisc-One is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

Important Safety Information (cont’d)
Talk to your doctor before resuming strenuous weight-bearing activities after treatment.

The side effects sometimes seen after Synvisc-One include (<2% each): pain, swelling, heat, redness, and/or fluid build-up in or around the knee. Tell your doctor if you experience any side effects after treatment with Synvisc-One.

Please see additional Important Safety Information on page 10.
Please see Patient Information on page 11.